Growth Hormone Secretagogues Explained: How CJC-1295 and Ipamorelin Work
What are growth hormone secretagogues? A clear look at how CJC-1295 and ipamorelin work, what the research shows, and how compounded peptide access works.
The idea of taking a peptide that tells your own body to release more growth hormone, rather than injecting synthetic HGH directly, sounds appealing and a little abstract at the same time. This guide breaks down what CJC-1295 and ipamorelin actually do at the receptor level, what the published research supports, and where the compounded peptide pathway fits legally.
Table of Contents
- What Growth Hormone Secretagogues Actually Do
- How CJC-1295 Stimulates the GHRH Receptor
- How Ipamorelin Targets the Ghrelin Receptor
- CJC-1295 vs Ipamorelin: A Side-by-Side Comparison
- What the Research Does Not Show
- How Compounded Peptides Reach a Patient Legally
- Who Should Talk to a Clinician About Peptide Options
- FAQ
What Growth Hormone Secretagogues Actually Do
A growth hormone secretagogue (GHS) is a compound that prompts the pituitary gland to release the body's own growth hormone, rather than introducing synthetic growth hormone directly. That distinction matters: a secretagogue works upstream, nudging a signaling pathway the body already has, instead of replacing the hormone itself.
CJC-1295 and ipamorelin are the two most frequently discussed peptides in this category, and they work through different receptors entirely. CJC-1295 is a GHRH-receptor agonist, meaning it binds the same receptor that the body's natural growth hormone-releasing hormone uses. Ipamorelin is a ghrelin-receptor agonist, acting on a separate receptor known as GHS-R1a.
This article uses a research-use framing throughout. Individual outcomes are not guaranteed, and nothing here should be read as a treatment recommendation for a specific person. Any clinical use requires an evaluation by a licensed clinician who can review a patient's full history before anything is prescribed.
How CJC-1295 Stimulates the GHRH Receptor
CJC-1295 is a synthetic analog of growth hormone-releasing hormone, designed to bind the GHRH receptor on the anterior pituitary. Structurally, it was built to resist the rapid breakdown that limits the body's natural GHRH and earlier peptide analogs like sermorelin.
A 2006 study by Teichman and colleagues, published in the Journal of Clinical Endocrinology & Metabolism and indexed on pubmed.ncbi.nlm.nih.gov, found that subcutaneous CJC-1295 produced sustained, dose-dependent increases in growth hormone and IGF-I levels in healthy adults over the course of the study period. That is the primary human pharmacology data most researchers cite when discussing this peptide.
It's worth being precise about what "sustained" means in that study. It refers to a longer half-life compared with earlier GHRH analogs, allowing less frequent dosing in the research protocol, not to a one-time or permanent effect on hormone levels. Once a dosing period ends, hormone levels are expected to return toward baseline over time, consistent with how the receptor pathway is understood to function.
How Ipamorelin Targets the Ghrelin Receptor
Ipamorelin is a pentapeptide classified as a selective growth hormone secretagogue, meaning it acts on the ghrelin receptor (GHS-R1a) rather than the GHRH receptor that CJC-1295 targets. Because it works through a separate pathway, researchers have studied it independently rather than treating it as a variant of GHRH-based compounds.
Foundational research by Raun and colleagues in 1998, also indexed on pubmed.ncbi.nlm.nih.gov, described ipamorelin as the first selective GHS identified with high GH-releasing potency in preclinical models, with a comparatively narrow effect on other pituitary hormones such as cortisol and prolactin.
That word "selective" is doing specific work here. In the cited research, it describes a comparatively narrow hormonal effect profile observed in preclinical models, not a safety guarantee for human use. Preclinical data and human clinical data are not interchangeable, and the distinction matters when reading peptide research.
What to remember: CJC-1295 and ipamorelin were studied through two different receptor systems in two different types of research (human pharmacology for CJC-1295, preclinical selectivity work for ipamorelin). Neither study measured muscle gain, fat loss, or sleep quality as an outcome.
CJC-1295 vs Ipamorelin: A Side-by-Side Comparison
The two peptides are often discussed together because their mechanisms are complementary rather than overlapping. Here is how the cited literature characterizes each one:
| Characteristic | CJC-1295 | Ipamorelin |
|---|---|---|
| Receptor target | GHRH receptor (anterior pituitary) | Ghrelin receptor (GHS-R1a) |
| Mechanism class | GHRH-receptor agonist | Selective growth hormone secretagogue |
| Primary cited research | Teichman et al., 2006, human pharmacology study | Raun et al., 1998, preclinical selectivity study |
| Reported hormone effect | Sustained, dose-dependent GH and IGF-I increase in the study period | High GH-releasing potency with narrow effect on cortisol/prolactin in preclinical models |
| Study type | Clinical (healthy adult subjects) | Preclinical (in vitro and in vivo models) |
Because the two peptides act on distinct receptors, the mechanistic rationale researchers cite for discussing them together is that a GHRH-receptor signal and a ghrelin-receptor signal are separate inputs into the same downstream pituitary process. That is a mechanism-level observation, not a claim about a specific combined outcome, and no source reviewed for this article measured the two peptides used together in a controlled human trial.
What the Research Does Not Show
Neither CJC-1295 nor ipamorelin is an FDA-approved medication. FDA approval applies to specific branded pharmaceutical molecules, a regulatory category distinct from the 503A compounding pathway used for individualized peptide prescriptions, as described on fda.gov. Compounded preparations of these peptides follow that separate pathway rather than the standard drug approval process.
It's also worth being direct about the size and scope of the available research. Most published data on these two peptides come from small clinical pharmacology studies, like the Teichman 2006 trial, and preclinical work, like the Raun 1998 paper, rather than large-scale outcome trials in specific patient populations. That's a meaningfully different evidence base than what exists for an approved pharmaceutical.
Peptide research literature generally describes mechanisms and short-term hormone changes measured in a study setting. It does not document guaranteed results for muscle gain, fat loss, sleep quality, or recovery in an individual person, and no responsible reading of this literature supports that kind of claim.
How Compounded Peptides Reach a Patient Legally
When a peptide like CJC-1295 or ipamorelin is prescribed, the pathway works differently than buying an over-the-counter product. A patient is evaluated by a licensed clinician first, and if that clinician determines a prescription is appropriate, it is then prescribed by a licensed clinician and compounded and dispensed by a 503A partner pharmacy, not manufactured or handled by the marketing platform itself.
On the LodeRx platform, that separation of roles is structural, not just a disclosure line. LodeRx is a marketing brand operated by BRMR LLC; it does not perform clinical evaluations, write prescriptions, or handle protected health information. Clinical evaluation is performed by EliteCare, whose clinicians are state-licensed across all 50 states, and any resulting prescription is compounded and dispensed by RxAve and other 503A partner pharmacies. That division matters for anyone trying to understand who is actually accountable for which part of the process.
LodeRx also holds LegitScript Healthcare Merchant Certification, certificate 50431222, effective July 30, 2026. That certification reflects healthcare merchant compliance and accreditation review; it is not FDA approval and not a medical endorsement of any specific peptide or outcome.
Who Should Talk to a Clinician About Peptide Options
General candidacy considerations that a clinician typically reviews before any peptide conversation include:
- Age and overall health history relevant to pituitary or metabolic function
- Baseline bloodwork, including IGF-1, since this hormone is directly relevant to how a GHRH- or ghrelin-receptor pathway might be interpreted
- Current medications, to check for interactions or contraindications
- Prior hormone-related diagnoses, including any pituitary, thyroid, or metabolic condition
A current bloodwork panel is a reasonable starting point before any peptide conversation, since baseline IGF-1 and metabolic markers determine whether a secretagogue discussion is even clinically relevant for that person. Without that baseline data, a peptide conversation is speculative rather than individualized.
This article is general education, not an individual treatment recommendation. Any decision about growth hormone secretagogues should follow a one-on-one clinical evaluation, not a generic article, a forum thread, or a peptide vendor's marketing claims.
FAQ
What is a growth hormone secretagogue?
A growth hormone secretagogue is a compound that signals the pituitary gland to release more of the body's own growth hormone. CJC-1295 does this through the GHRH receptor, while ipamorelin acts on the ghrelin receptor. Both are studied in clinical pharmacology research, not approved as standalone brand-name drugs.
Is CJC-1295 the same as ipamorelin?
No. They work through different receptors: CJC-1295 is a GHRH-receptor analog, and ipamorelin is a selective ghrelin-receptor agonist. Researchers often discuss them together because their mechanisms are complementary, but published studies evaluate them separately.
Are CJC-1295 and ipamorelin FDA-approved?
No. FDA approval applies to specific branded pharmaceutical molecules. Compounded peptide preparations like CJC-1295 and ipamorelin are prepared under a 503A pharmacy pathway following an individual prescription, which is a different regulatory framework than FDA drug approval.
How long does it take to notice an effect from GH secretagogues?
Published pharmacology studies, such as Teichman et al. (2006), measured hormone level changes (GH and IGF-I) over weeks of dosing in a research setting. Individual response timing varies, and no source in this article supports a specific universal timeline for subjective outcomes.
Who can prescribe growth hormone secretagogues?
Only a licensed clinician can evaluate a patient and, if appropriate, write a prescription. On the LodeRx platform, EliteCare's state-licensed clinicians perform that evaluation, and any resulting prescription is compounded and dispensed by a 503A partner pharmacy such as RxAve.
If you're weighing whether a peptide conversation makes sense for you, the next concrete step is to review your candidacy for peptide therapy with a licensed clinician, which typically starts with a current bloodwork panel. You can also read more about how compounded medications differ from FDA-approved drugs and how the LodeRx evaluation and prescribing process works before you start.